DNA test may help doctors personalize heart failure treatment

NCT ID NCT07054489

Recruiting now Knowledge-focused Sponsor: David Lanfear Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study explores whether a person's genetic makeup can guide how doctors prescribe beta-blockers for heart failure with mildly reduced pumping ability. Ten participants will receive beta-blocker therapy guided by their polygenic score, and researchers will measure changes in heart function using MRI. The goal is to see if genetics can make treatment more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta blocker
What this could lead to: If successful, this could show that genetic testing helps doctors choose the right dose of beta-blocker for heart failure patients, leading to more personalized treatment.
What could go wrong: This is a very small early study with only 10 participants, so results may not apply to everyone. It is testing a method, not a new drug, so it won't directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE POLYGENIC SCORE

Contacts and locations

Locations

Henry Ford Health
RECRUITING

Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.